XOMA (NASDAQ:XOMA) Lowered to Sell Rating by StockNews.com

StockNews.com lowered shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a report released on Wednesday morning.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $123.00 price target on shares of XOMA in a report on Tuesday.

XOMA Price Performance

Shares of NASDAQ:XOMA opened at $25.74 on Wednesday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a twelve month low of $18.57 and a twelve month high of $35.00. The company’s 50 day moving average is $29.20 and its 200 day moving average is $27.94. The company has a market cap of $303.29 million, a PE ratio of -7.40 and a beta of 0.92.

Insider Buying and Selling at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares in the company, valued at $1,047,621.05. This trade represents a 38.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 7.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On XOMA

A number of large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in shares of XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares in the last quarter. Barclays PLC raised its position in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares during the last quarter. Ellsworth Advisors LLC purchased a new stake in XOMA during the 3rd quarter valued at about $516,000. Finally, Bank of New York Mellon Corp raised its holdings in XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after acquiring an additional 1,968 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.